Drugmakers move to defend the 340B rebate pilot as hospitals return to court
The fight over the 340B Rebate Model Pilot Program has sharpened into a three-way legal contest: hospitals seeking to stop the program, the federal government defending it, and now drugmakers and their trade group moving to enter the case on the government’s side. AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim filed a motion to intervene in the Maine federal lawsuit after the American Hospital Association, the Maine Hospital Association, and three community-based providers asked for a temporary restraining order against the pilot. PhRMA filed a similar motion a day later.
The dispute centers on a basic but financially consequential shift. Under the pilot, safety-net hospitals would no longer receive the 340B discount upfront in the usual way. Instead, manufacturers would issue rebates after the sale, a structure that changes cash flow, billing, compliance, and dispute resolution across the drug supply chain.
Drugmakers and PhRMA say they have direct interests at stake because the pilot could shape future rebate programs well beyond the current cohort of drugs and manufacturers. Their filings also argue that HHS may not fully represent the operational and financial burdens manufacturers say they would face if the court blocks the pilot a second time. PhRMA went further, pointing to the first version of the program and saying its warnings proved accurate after courts prevented implementation and one manufacturer later paid millions of dollars per week in duplicate discounts during early 2026.
Hospitals argue the pilot was built on flawed cost estimates
Hospitals returned to the same Maine courthouse that blocked the earlier iteration of the program before it could begin in 2026. Their complaint seeks to halt the revised pilot before its Jan. 1 launch and argues that HHS and the Health Resources and Services Administration ignored substantial comments about compliance costs and alternative approaches.
The gap between the parties is enormous. Hospitals say the administrative burden would exceed $1 billion per year across the sector, while the government’s estimate sits at about $537.2 million per year across all covered entities. The updated pilot also broadened the scope of participation, with HRSA saying last week that the second iteration includes 21 drugs and 10 manufacturers. Those additions may look procedural on paper, but in practice they expand the number of claims, rebate disputes, and data exchanges that hospitals and manufacturers would have to reconcile in real time.
For providers, the fear is not abstract. A rebate model shifts reimbursement away from the point of purchase and forces hospitals to front the cost of therapy before any manufacturer payment arrives. In a safety-net setting, where margins are already thin and pharmacy spending is tied directly to patient access, delayed repayment can strain working capital and complicate medication availability. The hospitals’ position is that the government cannot alter that architecture without fully accounting for downstream effects on care delivery.
The legal strategy mirrors last year’s successful block
The hospital industry is not improvising here. It is returning to a legal playbook that worked before, when the same court and a corresponding appellate court blocked the first 340B rebate initiative. Judges in that earlier round said the rollout was hasty and did not properly collect or incorporate public input before the administration moved ahead.
After those rulings, HRSA withdrew the first version and came back with a longer comment process. The revised effort added guardrails meant to answer provider objections, including a requirement that the IT systems for submitting 340B purchase claims be built and maintained by drug manufacturers and a directive that rebate denials include “rationale and specific documentation” for the denial. Those guardrails matter operationally, but they do not resolve the central dispute over whether the program itself is lawful, workable, or consistent with the statute’s structure.
The 340B program was designed to help covered entities stretch scarce federal resources and preserve access for low-income and medically vulnerable patients. Critics, including HHS, argue that the program has expanded far beyond that original purpose and can distort incentives across large health systems. Supporters counter that the hospitals relying on 340B often deliver uncompensated or undercompensated care in communities with limited alternatives, so any delay or reduction in drug savings can ripple directly into staffing, infusion services, and outpatient access.
Duplicate discounts and future rebate policy remain the core fault line
PhRMA’s intervention filing returns to one of the industry’s most persistent concerns: duplicate discounts. Drugmakers have long argued that the 340B discount can be layered alongside Medicaid rebates in ways that create overlapping price concessions on the same drug. The hospital side says such events are rare and that manufacturers have overstated the problem to justify more intrusive controls. Courts have already told drugmakers that HHS, not private manufacturers, has the authority to impose a rebate model to address the issue.
The broader policy context is moving in the same direction. Policymakers and drug companies have repeatedly tried to place limits on 340B, and HHS has said the program has swollen into something far removed from its original intent. The department has also signaled a major cut to the government’s 340B drug rebate rate, from 6% above average sales price to 33.4% below average sales price. Hospital groups have already indicated they plan to challenge that change in court as well.
What makes this round especially fraught is that the pilot may now function as a template for later federal efforts. If the government succeeds, rebate-based reimbursement could become a more durable enforcement tool in 340B oversight. If hospitals prevail again, the administration may find itself boxed in on how it can police the program’s pricing rules and duplicate-discount concerns. Either way, the litigation is now about more than a pilot program scheduled to start in January; it is about who gets to define the mechanics of 340B going forward.
The next legal filing will likely decide whether manufacturers get a seat at the table before the merits are reached. That question is procedural on its face, but the practical stakes are immediate: who bears the cost of delay, who controls the flow of data, and whether the court will let a second 340B rebate model survive long enough to operate.